Repair mechanisms help glioblastoma resist treatment

Journal of Clinical Neuroscience

Volumn 22, Issue 1, 2015, Pages 14-20

  Atkins, Ryan J ^a   Ng, Wayne ^a,b   Stylli, Stanley S ^a,b   Hovens, Christopher M ^a,c   Kaye, Andrew H ^a,b  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL MELBOURNE HOSPITAL   (Australia)

^c Australian Prostate Cancer Research Centre at Epworth   (Australia)

Author keywords

Base excision repair; Glioma resistance; MGMT; PARP; Temozolomide chemotherapy

Indexed keywords

CARMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 2; NIMUSTINE; OLAPARIB; TEMOZOLOMIDE; VELIPARIB; XRCC1 PROTEIN; DNA LIGASE; DNA METHYLTRANSFERASE; MGMT PROTEIN, HUMAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; TUMOR SUPPRESSOR PROTEIN;

CANCER RESISTANCE; CHEMORADIOTHERAPY; CLINICAL TRIAL (TOPIC); DNA END JOINING REPAIR; DNA METHYLATION; DNA REPLICATION; DOUBLE STRANDED DNA BREAK; DRUG EFFICACY; ENZYME ACTIVE SITE; ENZYME INHIBITION; EXCISION REPAIR; GLIOBLASTOMA; HUMAN; NONHUMAN; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SINGLE STRANDED DNA BREAK; TREATMENT FAILURE; TREATMENT RESPONSE; BRAIN NEOPLASMS; DNA REPAIR; METABOLISM;

BRAIN NEOPLASMS; DNA MODIFICATION METHYLASES; DNA REPAIR; DNA REPAIR ENZYMES; GLIOBLASTOMA; HUMANS; POLY(ADP-RIBOSE) POLYMERASES; TUMOR SUPPRESSOR PROTEINS;

EID: 84920678580     PISSN: 09675868     EISSN: 15322653     Source Type: Journal    
DOI: 10.1016/j.jocn.2014.09.003     Document Type: Review

References (132)

1. J.C. Buckner, P.D. Brown, and B.P. O'Neill Central nervous system tumors Mayo Clin Proc 82 2007 1271 1286
2. R.J. Atkins, J. Dimou, and L. Paradiso Regulation of glycogen synthase kinase-3 beta (GSK-3β) by the Akt pathway in gliomas J Clin Neurosci 19 2012 1558 1563
3. R.J. Atkins, S.S. Stylli, and R.B. Luwor Glycogen synthase kinase-3beta (GSK-3beta) and its dysregulation in glioblastoma multiforme J Clin Neurosci 20 2013 1185 1192
4. S.S. Stylli, A.H. Kaye, and L. MacGregor Photodynamic therapy of high grade glioma - long term survival J Clin Neurosci 12 2005 389 398
5. S.S. Stylli, and A.H. Kaye Photodynamic therapy of cerebral glioma - a review. Part II - clinical studies J Clin Neurosci 13 2006 709 717
6. S.S. Stylli, M. Howes, and L. MacGregor Photodynamic therapy of brain tumours: evaluation of porphyrin uptake versus clinical outcome J Clin Neurosci 11 2004 584 596
7. S. Galban, B. Lemasson, and T.M. Williams DW-MRI as a biomarker to compare therapeutic outcomes in radiotherapy regimens incorporating temozolomide or gemcitabine in glioblastoma PLoS One 7 2012 e35857
8. P. Kleihues, and H. Ohgaki Primary and secondary glioblastomas: from concept to clinical diagnosis Neuro Oncol 1 1999 44 51
9. E.A. Maher, F.B. Furnari, and R.M. Bachoo Malignant glioma: genetics and biology of a grave matter Genes Dev 15 2001 1311 1333
10. H. Ohgaki, P. Dessen, and B. Jourde Genetic pathways to glioblastoma: a population-based study Cancer Res 64 2004 6892 6899
11. R. Stupp, M.E. Hegi, and W.P. Mason Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial Lancet Oncol 10 2009 459 466
12. R. Stupp, W.P. Mason, and M.J. van den Bent Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma N Engl J Med 352 2005 987 996
13. B. Tran, and M.A. Rosenthal Survival comparison between glioblastoma multiforme and other incurable cancers J Clin Neurosci 17 2010 417 421
14. M.E. Hegi, A.C. Diserens, and T. Gorlia MGMT gene silencing and benefit from temozolomide in glioblastoma N Engl J Med 352 2005 997 1003
15. M.E. Hegi, L. Liu, and J.G. Herman Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity J Clin Oncol 26 2008 4189 4199
16. D. Sturm, H. Witt, and V. Hovestadt Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma Cancer Cell 22 2012 425 437
17. E.H. Raabe, and C.G. Eberhart Methylome alterations "mark" new therapeutic opportunities in glioblastoma Cancer Cell 22 2012 417 418
18. R. Martinez, and M. Esteller The DNA methylome of glioblastoma multiforme Neurobiol Dis 39 2010 40 46
19. A. Sami, and M. Karsy Targeting the PI3K/AKT/mTOR signaling pathway in glioblastoma: novel therapeutic agents and advances in understanding Tumour Biol 34 2013 1991 2002
20. M. Rossi, L. Magnoni, and C. Miracco Beta-catenin and Gli1 are prognostic markers in glioblastoma Cancer Biol Ther 11 2011 753 761
21. B. Zhao, K. Tumaneng, and K.L. Guan The Hippo pathway in organ size control, tissue regeneration and stem cell self-renewal Nat Cell Biol 13 2011 877 883
22. M. Kamino, M. Kishida, and T. Kibe Wnt-5a signaling is correlated with infiltrative activity in human glioma by inducing cellular migration and MMP-2 Cancer Sci 102 2011 540 548
23. P.Y. Wen, E.Q. Lee, and D.A. Reardon Current clinical development of PI3K pathway inhibitors in glioblastoma Neuro Oncol 14 2012 819 829
24. H.K. Gan, A.H. Kaye, and R.B. Luwor The EGFRvIII variant in glioblastoma multiforme J Clin Neurosci 16 2009 748 754
25. M.L. Wong, A. Prawira, and A.H. Kaye Tumour angiogenesis: its mechanism and therapeutic implications in malignant gliomas J Clin Neurosci 16 2009 1119 1130
26. R.B. Luwor, S.S. Stylli, and A.H. Kaye The role of Stat3 in glioblastoma multiforme J Clin Neurosci 20 2013 907 911
27. P.D. Brown, S. Krishnan, and J.N. Sarkaria Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177 J Clin Oncol 26 2008 5603 5609
28. M.D. Prados, S.M. Chang, and N. Butowski Phase II study of erlotinib plus temozolomide during and after radiation therapy in patients with newly diagnosed glioblastoma multiforme or gliosarcoma J Clin Oncol 27 2009 579 584
29. J.J. Raizer, L.E. Abrey, and A.B. Lassman A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy Neuro Oncol 12 2010 95 103
30. M.R. Gilbert, J.J. Dignam, and T.S. Armstrong A randomized trial of bevacizumab for newly diagnosed glioblastoma N Engl J Med 370 2014 699 708
31. O. Keunen, M. Johansson, and A. Oudin Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma Proc Natl Acad Sci U S A 108 2011 3749 3754
32. S.S. Stylli, A.H. Kaye, and P. Lock Invadopodia: at the cutting edge of tumour invasion J Clin Neurosci 15 2008 725 737
33. S.S. Stylli, S.T. I, and A.H. Kaye Prognostic significance of Tks5 expression in gliomas J Clin Neurosci 19 2012 436 442
34. D.A. Reardon, L.B. Nabors, and R. Stupp Cilengitide: an integrin-targeting arginine-glycine-Aspartic acid peptide with promising activity for glioblastoma multiforme Expert Opin Investig Drugs 17 2008 1225 1235
35. D.A. Reardon, and D. Cheresh Cilengitide: a prototypic integrin inhibitor for the treatment of glioblastoma and other malignancies Genes Cancer 2 2011 1159 1165
36. R. Stupp, M.E. Hegi, and T. Gorlia Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma and methylated O6-methylguanine-DNA methyltransferase (MGMT) gene promoter: key results of the multicenter, randomized, open-label, controlled, phase III CENTRIC study J Clin Oncol 15 2014 1100 1108
37. A. Sahgal, L. Ma, and E. Chang Advances in technology for intracranial stereotactic radiosurgery Technol Cancer Res Treat 8 2009 271 280
38. S. Lorentini, D. Amelio, and M.G. Giri IMRT or 3D-CRT in glioblastoma? A dosimetric criterion for patient selection Technol Cancer Res Treat 12 2013 411 420
39. W.P. Levin, H. Kooy, and J.S. Loeffler Proton beam therapy Br J Cancer 93 2005 849 854
40. G.L. Dianov Base excision repair targets for cancer therapy Am J Cancer Res 1 2011 845 851
41. A.J. Chalmers The potential role and application of PARP inhibitors in cancer treatment Br Med Bull 89 2009 23 40
42. J. Bartkova, Z. Horejsi, and K. Koed DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis Nature 434 2005 864 870
43. H. Farmer, N. McCabe, and C.J. Lord Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy Nature 434 2005 917 921
44. H.E. Bryant, N. Schultz, and H.D. Thomas Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase Nature 434 2005 913 917
45. M. Jamal, B.H. Rath, and E.S. Williams Microenvironmental regulation of glioblastoma radioresponse Clin Cancer Res 16 2010 6049 6059
46. A.K. McCullough, M.L. Dodson, and R.S. Lloyd Initiation of base excision repair: glycosylase mechanisms and structures Annu Rev Biochem 68 1999 255 285
47. L. Barazzuol, R. Jena, and N.G. Burnet Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma Radiat Oncol 8 2013 65
48. M. Wang, W. Wu, and W. Wu PARP-1 and Ku compete for repair of DNA double strand breaks by distinct NHEJ pathways Nucleic Acids Res 34 2006 6170 6182
49. M. Citarelli, S. Teotia, and R.S. Lamb Evolutionary history of the poly(ADP-ribose) polymerase gene family in eukaryotes BMC Evol Biol 10 2010 308
50. J.P. Gagne, M. Rouleau, and G.G. Poirier Structural biology. PARP-1 activation-bringing the pieces together Science 336 2012 678 679
51. A.J. Chalmers Overcoming resistance of glioblastoma to conventional cytotoxic therapies by the addition of PARP inhibitors Anticancer Agents Med Chem. 10 2010 520 533
52. P. Bouwman, and J. Jonkers Molecular pathways: how can BRCA-mutated tumors become resistant to PARP inhibitors? Clin Cancer Res 20 2014 540 547
53. P.C. Fong, D.S. Boss, and T.A. Yap Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers N Engl J Med 361 2009 123 134
54. M.W. Audeh, J. Carmichael, and R.T. Penson Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial Lancet 376 2010 245 251
55. J. Ledermann, P. Harter, and C. Gourley Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer N Engl J Med 366 2012 1382 1392
56. S.B. Kaye, J. Lubinski, and U. Matulonis Phase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer J Clin Oncol 30 2012 372 379
57. E.A. Eisenhauer, P. Therasse, and J. Bogaerts New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 2009 228 247
58. R.A. Dent, G.J. Lindeman, and M. Clemons Phase I trial of the oral PARP inhibitor olaparib in combination with paclitaxel for first- or second-line treatment of patients with metastatic triple-negative breast cancer Breast Cancer Res 15 2013 R88
59. M. Srivastava, M. Nambiar, and S. Sharma An inhibitor of nonhomologous end-joining abrogates double-strand break repair and impedes cancer progression Cell 151 2012 1474 1487
60. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). A phase I study of ABT-888, an oral inhibitor of poly(ADP-ribose) polymerase and temozolomide in children with recurrent/refractory CNS tumors. 2009-[cited 2014 June 17]: Available from: http://clinicaltrials.gov/show/NCT00994071 NLM identifier NCT00994071.
61. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Olaparib and temozolomide in treating patients with relapsed glioblastoma. 2011-[cited 2014 June 17]: Available from: http://clinicaltrials.gov/show/NCT01390571 NLM identifier NCT01390571.
62. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Study of the poly (ADP-ribose) polymerase-1 (PARP-1) inhibitor BSI-201 in patients with newly diagnosed malignant glioma. 2008-[cited 2014 June 17]: Available from: http://clinicaltrials.gov/show/NCT00687765 NLM identifier NCT.
63. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Study of poly (ADP-ribose) polymerase (PARP) inhibitor E7016 in combination with temozolomide in subjects with advanced solid tumors. 2010-[cited 2014 June 17]: Available from: http://clinicaltrials.gov/show/NCT01127178 NLM identifier NCT00687765.
64. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). O6-benzylguanine and temozolomide in treating young patients with recurrent or progressive gliomas or brain stem tumors. 2006-[cited 2014 June 17]: Available from: http://clinicaltrials.gov/show/NCT00275002 NLM identifier NCT00275002.
65. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Ph I 5-day temozolomide + O6-BG in treatment of Pts w recurrent/progressive GBM. 2008-[cited 2014 June 17]: Available from: http://clinicaltrials.gov/show/NCT00612989 NLM identifier NCT00612989.
66. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). O6-benzylguanine and temozolomide in combination with genetically modified peripheral blood stem cells in newly diagnosed glioblastoma multiforme. 2010-[cited 2014 June 17]: Available from: http://clinicaltrials.gov/show/NCT01269424 NLM identifier NCT.
67. ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). Ph. II temozolocorrt in xmlmide + O6-BG in treatment of Pts w temozolomide-resistant malignant glioma. 2008-[cited 2014 June 17]: Available from: http://clinicaltrials.gov/show/NCT00613093 NLM identifier NCT00613093.
68. B.J. Denny, R.T. Wheelhouse, and M.F. Stevens NMR and molecular modeling investigation of the mechanism of activation of the antitumor drug temozolomide and its interaction with DNA Biochemistry 33 1994 9045 9051
69. B. Kaina, M. Christmann, and S. Naumann MGMT: key node in the battle against genotoxicity, carcinogenicity and apoptosis induced by alkylating agents DNA Repair (Amst) 6 2007 1079 1099
70. J.F. Parkinson, H.T. Wheeler, and K.L. McDonald Contribution of DNA repair mechanisms to determining chemotherapy response in high-grade glioma J Clin Neurosci 15 2008 1 8
71. C. Gouws, and P.J. Pretorius O6-methylguanine-DNA methyltransferase (MGMT): can function explain a suicidal mechanism? Med Hypotheses 77 2011 857 860
72. L.C. Erickson, G. Laurent, and N.A. Sharkey DNA cross-linking and monoadduct repair in nitrosourea-treated human tumour cells Nature 288 1980 727 729
73. A. Shiraishi, K. Sakumi, and M. Sekiguchi Increased susceptibility to chemotherapeutic alkylating agents of mice deficient in DNA repair methyltransferase Carcinogenesis 21 2000 1879 1883
74. S.L. Gerson MGMT: its role in cancer aetiology and cancer therapeutics Nat Rev Cancer 4 2004 296 307
75. J.R. Silber, A. Blank, and M.S. Bobola Lack of the DNA repair protein O6-methylguanine-DNA methyltransferase in histologically normal brain adjacent to primary human brain tumors Proc Natl Acad Sci U S A 93 1996 6941 6946
76. M. Citron, R. Decker, and S. Chen O6-methylguanine-DNA methyltransferase in human normal and tumor tissue from brain, lung, and ovary Cancer Res 51 1991 4131 4134
77. F.Y. Chen, L.C. Harris, and J.S. Remack Cytoplasmic sequestration of an O6-methylguanine-DNA methyltransferase enhancer binding protein in DNA repair-deficient human cells Proc Natl Acad Sci U S A 94 1997 4348 4353
78. F.V. Jacinto, and M. Esteller MGMT hypermethylation: a prognostic foe, a predictive friend DNA Repair (Amst) 6 2007 1155 1160
79. L. Liu, and S.L. Gerson Targeted modulation of MGMT: clinical implications Clin Cancer Res 12 2006 328 331
80. D.B. Yarosh The role of O6-methylguanine-DNA methyltransferase in cell survival, mutagenesis and carcinogenesis Mutat Res 145 1985 1 16
81. J.N. Sarkaria, G.J. Kitange, and C.D. James Mechanisms of chemoresistance to alkylating agents in malignant glioma Clin Cancer Res 14 2008 2900 2908
82. M.S. Bobola, S.H. Tseng, and A. Blank Role of O6-methylguanine-DNA methyltransferase in resistance of human brain tumor cell lines to the clinically relevant methylating agents temozolomide and streptozotocin Clin Cancer Res 2 1996 735 741
83. M.C. Walker, J.R. Masters, and G.P. Margison O6-Alkylguanine-DNA-Alkyltransferase activity and nitrosourea sensitivity in human cancer cell lines Br J Cancer 66 1992 840 843
84. M.J. Hickman, and L.D. Samson Role of DNA mismatch repair and p53 in signaling induction of apoptosis by alkylating agents Proc Natl Acad Sci U S A 96 1999 10764 10769
85. D. Pletsas, E.A. Garelnabi, and L. Li Synthesis and quantitative structure-Activity relationship of imidazotetrazine prodrugs with activity independent of O6-Methylguanine-DNA-methyltransferase, DNA mismatch repair and p53 J Med Chem 56 2013 7120 7132
86. S.H. Doak, K. Brusehafer, and E. Dudley No-observed effect levels are associated with up-regulation of MGMT following MMS exposure Mutat Res 648 2008 9 14
87. M.S. Bobola, D.D. Kolstoe, and A. Blank Minimally cytotoxic doses of temozolomide produce radiosensitization in human glioblastoma cells regardless of MGMT expression Mol Cancer Ther 9 2010 1208 1218
88. A.O. von Bueren, M.D. Bacolod, and C. Hagel Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours Br J Cancer 107 2012 1399 1408
89. C.L. Cheng, S.P. Johnson, and S.T. Keir Poly(ADP-ribose) polymerase-1 inhibition reverses temozolomide resistance in a DNA mismatch repair-deficient malignant glioma xenograft Mol Cancer Ther 4 2005 1364 1368
90. R. Pepponi, G. Marra, and M.P. Fuggetta The effect of O6-Alkylguanine-DNA alkyltransferase and mismatch repair activities on the sensitivity of human melanoma cells to temozolomide, 1,3-bis(2-chloroethyl)1-nitrosourea, and cisplatin J Pharmacol Exp Ther 304 2003 661 668
91. H. Kawate, K. Sakumi, and T. Tsuzuki Separation of killing and tumorigenic effects of an alkylating agent in mice defective in two of the DNA repair genes Proc Natl Acad Sci U S A 95 1998 5116 5120
92. L. Liu, S. Markowitz, and S.L. Gerson Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea Cancer Res 56 1996 5375 5379
93. G. Frosina DNA repair and resistance of gliomas to chemotherapy and radiotherapy Mol Cancer Res 7 2009 989 999
94. D.A. Bota, A. Desjardins, and J.A. Quinn Interstitial chemotherapy with biodegradable BCNU (Gliadel) wafers in the treatment of malignant gliomas Ther Clin Risk Manag 3 2007 707 715
95. K.W. Kohn Interstrand cross-linking of DNA by 1,3-bis(2-chloroethyl)-1-nitrosourea and other 1-(2-haloethyl)-1-nitrosoureas Cancer Res 37 1977 1450 1454
96. J.S. Lee, T.K. An, and G.S. Chae Evaluation of in vitro and in vivo antitumor activity of BCNU-loaded PLGA wafer against 9L gliosarcoma Eur J Pharm Biopharm 59 2005 169 175
97. G. Noel, R. Schott, and S. Froelich Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior Gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas Int J Radiat Oncol Biol Phys 82 2012 749 755
98. M.J. McGirt, K.D. Than, and J.D. Weingart Gliadel (BCNU) wafer plus concomitant temozolomide therapy after primary resection of glioblastoma multiforme J Neurosurg 110 2009 583 588
99. A. Bregy, A.H. Shah, and M.V. Diaz The role of Gliadel wafers in the treatment of high-grade gliomas Expert Rev Anticancer Ther 13 2013 1453 1461
100. J.G. Barr, and P.L. Grundy The effects of the NICE Technology Appraisal 121 (gliadel and temozolomide) on survival in high-grade glioma Br J Neurosurg 26 2012 818 822
101. M. Westphal, Z. Ram, and V. Riddle Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial Acta Neurochir (Wien) 148 2006 269 275 [discussion 275]
102. A. Silvani, P. Gaviani, and E.A. Lamperti Cisplatinum and BCNU chemotherapy in primary glioblastoma patients J Neurooncol 94 2009 57 62
103. A.J. Sawyer, J.K. Saucier-Sawyer, and C.J. Booth Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatment of intracranial tumors Drug Deliv Transl Res 1 2011 34 42
104. S. Sugiyama, Y. Yamashita, and T. Kikuchi Safety and efficacy of convection-enhanced delivery of ACNU, a hydrophilic nitrosourea, in intracranial brain tumor models J Neurooncol 82 2007 41 47
105. I.H. Kim, C.K. Park, and D.S. Heo Radiotherapy followed by adjuvant temozolomide with or without neoadjuvant ACNU-CDDP chemotherapy in newly diagnosed glioblastomas: a prospective randomized controlled multicenter phase III trial J Neurooncol 103 2011 595 602
106. Y. Wang, X. Chen, and Z. Zhang Comparison of the clinical efficacy of temozolomide (TMZ) versus nimustine (ACNU)-based chemotherapy in newly diagnosed glioblastoma Neurosurg Rev 37 2014 73 78
107. M. Esteller, S.R. Hamilton, and P.C. Burger Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia Cancer Res 59 1999 793 797
108. M. Esteller, J. Garcia-Foncillas, and E. Andion Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents N Engl J Med 343 2000 1350 1354
109. J. Felsberg, N. Thon, and S. Eigenbrod Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas Int J Cancer 129 2011 659 670
110. X. Qian, M.A. von Wronski, and T.P. Brent Localization of methylation sites in the human O6-methylguanine-DNA methyltransferase promoter: correlation with gene suppression Carcinogenesis 16 1995 1385 1390
111. B. Sedgwick, P.A. Bates, and J. Paik Repair of alkylated DNA: recent advances DNA Repair (Amst) 6 2007 429 442
112. M.E. Dolan, R.C. Moschel, and A.E. Pegg Depletion of mammalian O6-Alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents Proc Natl Acad Sci U S A 87 1990 5368 5372
113. S.L. Gerson Clinical relevance of MGMT in the treatment of cancer J Clin Oncol 20 2002 2388 2399
114. J.A. Quinn, S.X. Jiang, and D.A. Reardon Phase II trial of temozolomide plus o6-benzylguanine in adults with recurrent, temozolomide-resistant malignant glioma J Clin Oncol 27 2009 1262 1267
115. S.P. Zielske, and S.L. Gerson Lentiviral transduction of P140K MGMT into human CD34(+) hematopoietic progenitors at low multiplicity of infection confers significant resistance to BG/BCNU and allows selection in vitro Mol Ther 5 2002 381 387
116. B.A. Kramer, F.A. Lemckert, and I.E. Alexander Characterisation of a P140K mutant O6-methylguanine-DNA-methyltransferase (MGMT)-expressing transgenic mouse line with drug-selectable bone marrow J Gene Med 8 2006 1071 1085
117. J.L. Gori, B.C. Beard, and C. Ironside In vivo selection of autologous MGMT gene-modified cells following reduced-intensity conditioning with BCNU and temozolomide in the dog model Cancer Gene Ther 19 2012 523 529
118. B.C. Beard, G.D. Trobridge, and C. Ironside Efficient and stable MGMT-mediated selection of long-term repopulating stem cells in nonhuman primates J Clin Invest 120 2010 2345 2354
119. M. Xu-Welliver, S. Kanugula, and A.E. Pegg Isolation of human O6-Alkylguanine-DNA alkyltransferase mutants highly resistant to inactivation by O6-benzylguanine Cancer Res 58 1998 1936 1945
120. T.K. Hazra, R. Roy, and T. Biswas Specific recognition of O6-methylguanine in DNA by active site mutants of human O6-methylguanine-DNA methyltransferase Biochemistry 36 1997 5769 5776
121. J.S. Reese, X. Qin, and C.B. Ballas MGMT expression in murine bone marrow is a major determinant of animal survival after alkylating agent exposure J Hematother Stem Cell Res 10 2001 115 123
122. T. Neff, B.C. Beard, and L.J. Peterson Polyclonal chemoprotection against temozolomide in a large-Animal model of drug resistance gene therapy Blood 105 2005 997 1002
123. S.P. Zielske, J.S. Reese, and K.T. Lingas In vivo selection of MGMT(P140K) lentivirus-transduced human NOD/SCID repopulating cells without pretransplant irradiation conditioning J Clin Invest 112 2003 1561 1570
124. J.A. Quinn, A. Desjardins, and J. Weingart Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma J Clin Oncol 23 2005 7178 7187
125. Y. Liu, R. Prasad, and W.A. Beard Coordination of steps in single-nucleotide base excision repair mediated by apurinic/apyrimidinic endonuclease 1 and DNA polymerase beta J Biol Chem 282 2007 13532 13541
126. S.S. David, V.L. O'Shea, and S. Kundu Base-excision repair of oxidative DNA damage Nature 447 2007 941 950
127. D.O. Zharkov Base excision DNA repair Cell Mol Life Sci 65 2008 1544 1565
128. A.B. Robertson, A. Klungland, and T. Rognes DNA repair in mammalian cells: base excision repair: the long and short of it Cell Mol Life Sci 66 2009 981 993
129. J.L. Parsons, and R.H. Elder DNA N-glycosylase deficient mice. a tale of redundancy Mutat Res 531 2003 165 175
130. G. Frosina Overexpression of enzymes that repair endogenous damage to DNA Eur J Biochem 267 2000 2135 2149
131. M.A. Vickers, P. Vyas, and P.C. Harris Structure of the human 3-methyladenine DNA glycosylase gene and localization close to the 16p telomere Proc Natl Acad Sci U S A 90 1993 3437 3441
132. B.P. Engelward, A. Dreslin, and J. Christensen Repair-deficient 3-methyladenine DNA glycosylase homozygous mutant mouse cells have increased sensitivity to alkylation-induced chromosome damage and cell killing EMBO J 15 1996 945 952